Since it is less likely for cancer cells to develop acquired resistance when multiple RTKs are simultaneously inhibited up front, there is a rationale for using the PDGFRα and FGFR1 inhibitor combination as first-line therapy (Tan et al., 2016). Here, FGFR1 is linked to cancer.